Idexx Laboratories (IDXX) 128.88 $IDXX
Post Earnings Update: Idexx Laboratories Has Climbed 6.1% Higher in Past 2 Weeks (IDXX)
Comtex SmarTrend(R) - Mon May 12, 12:11PM CDT
Two weeks ago on April 25th, 2014 Idexx Laboratories (NASDAQ:IDXX) reported earnings and analysts, on average, expected earnings of $0.87 on sales of $361.4 million. The company actually reported EPS of $0.89 on sales of $360.2 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.2 million. Since the company's report, shares of Idexx Laboratories have risen from $123.75 to $131.30, representing a gain of 6.1% in the past 17 days.
Research and Markets: Global Veterinary Diagnostics Market by Products & by Animals to 2018: IDEXX Laboratories & VCA Antech Account for 45-50% Market Share
Business Wire - Thu May 08, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82drxt/veterinary) has announced the addition of the "Veterinary Diagnostics Market by Products & by Animals - Global Forecast to 2018" report to their offering.
Global Veterinary Diagnostics Market by Products & by Animals to 2018: IDEXX Laboratories & VCA Antech Account for 45-50% Market Share
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rpb5hm/veterinary) has announced the addition of the "Veterinary Diagnostics Market by Products & by Animals - Global Forecast to 2018" report to their offering. The global veterinary diagnostics market is expected to grow at a healthy CAGR during the forecast period of 2013 to 2018 and is estimated to be worth $4,200 million by 2018. The major players in the veterinary diagnostics market include IDEXX Laboratories (U.S.), VCA Antech Inc. (U.S.), Abaxis Corporation (U.S.), Heska Corporation (U.S.), Zoetis Inc. (U.S.), Mindray Medical (China), Neogen Corporation (U.S.), and Thermo Fisher Scientific Inc. (U.S.). Collectively, the top eight players accounted for nearly 75% of the global veterinary diagnostics market in 2012. IDEXX Laboratories (U.S.) and VCA Antech (U.S.) are the leading players, together accounting for around 45%-50% share in the global veterinary diagnostics market in 2012. IDEXX Laboratories has a diversified product portfolio, which includes a wide range of companion animal diagnostics products and livestock and poultry diagnostic products. The company has a strong presence in over 100 countries through its strong manufacturing and distribution facilities, which enables it to cater to a large customer base across the globe. It focuses on strengthening and streamlining its product portfolio for the veterinary diagnostics industry. Over the years, the veterinary diagnostics market has grown multi-fold, adapting various technologies from the human diagnostics segment. In the past decade, a number of new products have been launched in this market, which had a positive impact on the growth of this market. In this report, the global veterinary diagnostics market is segmented by products, type of animals, end-users, and geography. The veterinary diagnostics market is mainly classified by product into clinical chemistry, hematology analyzers, molecular diagnostics, immunodiagnostics, diagnostic imaging, and others. The animal market covers companion animals and food-producing animals. The report also discusses the key market drivers, restraints, and opportunities of the global veterinary diagnostics market and its sub-markets. The market is mainly driven by the increasing incidences of disease outbreaks, increasing companion animal market backed by the rise in the adoption of pets, increase in the disposable incomes, and the increasing incidences of zoonotic diseases. However, economic downturn and increasing adoption of vegetarian food inhibits the growth of the market to a certain extent. During the forecast period the clinical chemistry segment will continue to drive and dominate the veterinary diagnostics market. A majority share of this growth can be attributed to widening applications of various clinical assays in veterinary diagnostics industry. Furthermore, rising demand for clinical diagnostics tests for food-producing animals are also expected to drive the growth of the veterinary diagnostics market. Highly organized dairy sector, increased awareness towards prevention of diseases in livestock animals in order to meet the increased demand for meat and dairy products, and increasing number of farm animals is expected to fuel the demand for diagnostic tests during the forecast period of 2013-2018. Scope Products - Clinical Chemistry - Hematology Analyzers - Molecular Diagnostics - Immunodiagnostics - Diagnostics Imaging Animals - Companion - Food-producing - Dog - Livestock - Poultry - Swine Companies Mentioned - Abaxis, Inc. - Heska Corporation - Idexx Laboratories, Inc. - Idvet - Mindray Medical International Ltd. - Neogen Corporation - Thermo Fisher Scientific Inc. - Vca Antech, Inc. - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/rpb5hm/veterinary
IDEXX Laboratories to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
PR Newswire - Wed May 07, 3:05PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced today that it will participate in the Bank of America Merrill Lynch 2014 Healthcare Conference. Brian McKeon, Executive Vice President and Chief Financial Officer, is scheduled to make a presentation on the Company on Wednesday, May 14, 2014 at 5:00 p.m. PT, at the Encore at Wynn, Las Vegas, Nevada. Individuals can access the live audio webcast of the presentation through a link on the home page of the IDEXX Laboratories website, www.idexx.com. An archived edition of the presentation will be available for 14 days via the same link.
Omnicell Drops Despite Q1 Earnings & Revs Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:20AM CDT
Omnicell, Inc. (OMCL) reported first-quarter 2014 adjusted EPS of 19 cents.
Technical Briefing on Equities Reaching New high -- Research on B/E Aerospace, Nordion, Magellan Midstream Partners, and IDEXX Laboratories
PR Newswire - Tue May 06, 8:00AM CDT
The U.S. markets on Monday, May 5, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the session 0.19% higher at 1,884.66. During the trading session, eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include B/E Aerospace Inc. (NASDAQ: BEAV), Nordion Inc (NYSE: NDZ), Magellan Midstream Partners L.P. (NYSE: MMP) and IDEXX Laboratories Inc. (NASDAQ: IDXX). Free technical research on BEAV, NDZ, MMP and IDXX can be downloaded upon signing up at:
Q4 Earnings Beat, Revs Miss Ests at PetMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:19AM CDT
PetMed Express' (PETS) EPS of 23 cents in the fourth quarter of fiscal 2014 came in 2 cents ahead of the Zacks Consensus Estimate.
Hologic Up on Q2 Earnings Beat & Raised Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:50AM CDT
Shares of Hologic Inc. (HOLX) surged more than 8% to $22.74 after market-close on May 2 since the release of its second-quarter fiscal 2014 results.
IDEXX Laboratories Announces First Quarter Results
PR Newswire - Fri Apr 25, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the first quarter of 2014 increased 8% versus the prior year period to $360.2 million. Organic revenue growth1 was also 8%. Earnings per diluted share ("EPS"
for the quarter ended March 31, 2014 increased 10% from the prior year period to $0.89. The first quarter of 2013 included the retroactive extension of the federal research and development tax credit, and the associated tax benefit related to that quarter, which added $0.06 to first quarter 2013 EPS, and a loss resulting from a third-party service provider's bankruptcy, which reduced first quarter 2013 EPS by $0.05. As the research and development tax credit expired as of January 1, 2014, no benefit from this provision was included in first quarter 2014 results.
Varian Medical Systems Beats, Earnings Flat Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:12PM CDT
Varian Medical Systems (VAR) retained its earnings per share guidance between $4.22 and $4.34 for the year, including a 16-cent charge for a patent litigation settlement.
Intuitive Surgical Lags on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:00PM CDT
Intuitive Surgical's (ISRG) earnings lagged the Zacks Consensus Estimate by a wide margin of 67 cents
IDEXX Laboratories to Release 2014 First Quarter Financial Results
PR Newswire - Tue Apr 15, 1:30PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), has scheduled the release of its 2014 first quarter financial results for Friday, April 25, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Idexx Laboratories Larger Than S&P 500 Component LSI
TheOnlineInvestor.com - Mon Mar 31, 3:37PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Idexx Laboratories, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example LSI Corp , according to The...
Recognitions, Board Elections, Acquisitions, and Organizational Changes - Analyst Notes on Omnicare, Cooper, Mednax, IDEXX, and Hologic
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Omnicare Inc. (NYSE: OCR), The Cooper Companies Inc. (NYSE: COO), MEDNAX, Inc. (NYSE: MD), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Hologic Inc. (NASDAQ: HOLX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Idexx Laboratories Stock Rises 16.3% (IDXX)
Comtex SmarTrend(R) - Wed Mar 19, 5:15PM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 16.31% as of today's recent price of $123.74.
After Yesterday's Decline of 3.31%, Idexx Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 17, 6:10PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $123.64 to a high of $129.17. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $125.59 on volume of 627,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Idexx Laboratories (IDXX) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Mon Mar 17, 12:23PM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Idexx Laboratories Shares Up 20.2% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 12, 11:07AM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 20.18% as of today's recent price of $127.85.
IDEXX Laboratories names Daniel Junius as member of the board
M2 - Wed Mar 12, 7:59AM CDT
Diagnostics and information technology solutions for animal health care company IDEXX Laboratories (NASDAQ:IDXX) announced on Tuesday that Daniel M Junius has been elected as a member of the company's board of directors, with immediate effect.
Post Earnings Update: Idexx Laboratories Has Climbed 6.1% Higher in Past 2 Weeks (IDXX)
Comtex SmarTrend(R) - Mon May 12, 12:11PM CDT
Two weeks ago on April 25th, 2014 Idexx Laboratories (NASDAQ:IDXX) reported earnings and analysts, on average, expected earnings of $0.87 on sales of $361.4 million. The company actually reported EPS of $0.89 on sales of $360.2 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.2 million. Since the company's report, shares of Idexx Laboratories have risen from $123.75 to $131.30, representing a gain of 6.1% in the past 17 days.
Research and Markets: Global Veterinary Diagnostics Market by Products & by Animals to 2018: IDEXX Laboratories & VCA Antech Account for 45-50% Market Share
Business Wire - Thu May 08, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82drxt/veterinary) has announced the addition of the "Veterinary Diagnostics Market by Products & by Animals - Global Forecast to 2018" report to their offering.
Global Veterinary Diagnostics Market by Products & by Animals to 2018: IDEXX Laboratories & VCA Antech Account for 45-50% Market Share
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rpb5hm/veterinary) has announced the addition of the "Veterinary Diagnostics Market by Products & by Animals - Global Forecast to 2018" report to their offering. The global veterinary diagnostics market is expected to grow at a healthy CAGR during the forecast period of 2013 to 2018 and is estimated to be worth $4,200 million by 2018. The major players in the veterinary diagnostics market include IDEXX Laboratories (U.S.), VCA Antech Inc. (U.S.), Abaxis Corporation (U.S.), Heska Corporation (U.S.), Zoetis Inc. (U.S.), Mindray Medical (China), Neogen Corporation (U.S.), and Thermo Fisher Scientific Inc. (U.S.). Collectively, the top eight players accounted for nearly 75% of the global veterinary diagnostics market in 2012. IDEXX Laboratories (U.S.) and VCA Antech (U.S.) are the leading players, together accounting for around 45%-50% share in the global veterinary diagnostics market in 2012. IDEXX Laboratories has a diversified product portfolio, which includes a wide range of companion animal diagnostics products and livestock and poultry diagnostic products. The company has a strong presence in over 100 countries through its strong manufacturing and distribution facilities, which enables it to cater to a large customer base across the globe. It focuses on strengthening and streamlining its product portfolio for the veterinary diagnostics industry. Over the years, the veterinary diagnostics market has grown multi-fold, adapting various technologies from the human diagnostics segment. In the past decade, a number of new products have been launched in this market, which had a positive impact on the growth of this market. In this report, the global veterinary diagnostics market is segmented by products, type of animals, end-users, and geography. The veterinary diagnostics market is mainly classified by product into clinical chemistry, hematology analyzers, molecular diagnostics, immunodiagnostics, diagnostic imaging, and others. The animal market covers companion animals and food-producing animals. The report also discusses the key market drivers, restraints, and opportunities of the global veterinary diagnostics market and its sub-markets. The market is mainly driven by the increasing incidences of disease outbreaks, increasing companion animal market backed by the rise in the adoption of pets, increase in the disposable incomes, and the increasing incidences of zoonotic diseases. However, economic downturn and increasing adoption of vegetarian food inhibits the growth of the market to a certain extent. During the forecast period the clinical chemistry segment will continue to drive and dominate the veterinary diagnostics market. A majority share of this growth can be attributed to widening applications of various clinical assays in veterinary diagnostics industry. Furthermore, rising demand for clinical diagnostics tests for food-producing animals are also expected to drive the growth of the veterinary diagnostics market. Highly organized dairy sector, increased awareness towards prevention of diseases in livestock animals in order to meet the increased demand for meat and dairy products, and increasing number of farm animals is expected to fuel the demand for diagnostic tests during the forecast period of 2013-2018. Scope Products - Clinical Chemistry - Hematology Analyzers - Molecular Diagnostics - Immunodiagnostics - Diagnostics Imaging Animals - Companion - Food-producing - Dog - Livestock - Poultry - Swine Companies Mentioned - Abaxis, Inc. - Heska Corporation - Idexx Laboratories, Inc. - Idvet - Mindray Medical International Ltd. - Neogen Corporation - Thermo Fisher Scientific Inc. - Vca Antech, Inc. - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/rpb5hm/veterinary
IDEXX Laboratories to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
PR Newswire - Wed May 07, 3:05PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced today that it will participate in the Bank of America Merrill Lynch 2014 Healthcare Conference. Brian McKeon, Executive Vice President and Chief Financial Officer, is scheduled to make a presentation on the Company on Wednesday, May 14, 2014 at 5:00 p.m. PT, at the Encore at Wynn, Las Vegas, Nevada. Individuals can access the live audio webcast of the presentation through a link on the home page of the IDEXX Laboratories website, www.idexx.com. An archived edition of the presentation will be available for 14 days via the same link.
Omnicell Drops Despite Q1 Earnings & Revs Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:20AM CDT
Omnicell, Inc. (OMCL) reported first-quarter 2014 adjusted EPS of 19 cents.
Technical Briefing on Equities Reaching New high -- Research on B/E Aerospace, Nordion, Magellan Midstream Partners, and IDEXX Laboratories
PR Newswire - Tue May 06, 8:00AM CDT
The U.S. markets on Monday, May 5, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the session 0.19% higher at 1,884.66. During the trading session, eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include B/E Aerospace Inc. (NASDAQ: BEAV), Nordion Inc (NYSE: NDZ), Magellan Midstream Partners L.P. (NYSE: MMP) and IDEXX Laboratories Inc. (NASDAQ: IDXX). Free technical research on BEAV, NDZ, MMP and IDXX can be downloaded upon signing up at:
Q4 Earnings Beat, Revs Miss Ests at PetMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:19AM CDT
PetMed Express' (PETS) EPS of 23 cents in the fourth quarter of fiscal 2014 came in 2 cents ahead of the Zacks Consensus Estimate.
Hologic Up on Q2 Earnings Beat & Raised Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:50AM CDT
Shares of Hologic Inc. (HOLX) surged more than 8% to $22.74 after market-close on May 2 since the release of its second-quarter fiscal 2014 results.
IDEXX Laboratories Announces First Quarter Results
PR Newswire - Fri Apr 25, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the first quarter of 2014 increased 8% versus the prior year period to $360.2 million. Organic revenue growth1 was also 8%. Earnings per diluted share ("EPS"
for the quarter ended March 31, 2014 increased 10% from the prior year period to $0.89. The first quarter of 2013 included the retroactive extension of the federal research and development tax credit, and the associated tax benefit related to that quarter, which added $0.06 to first quarter 2013 EPS, and a loss resulting from a third-party service provider's bankruptcy, which reduced first quarter 2013 EPS by $0.05. As the research and development tax credit expired as of January 1, 2014, no benefit from this provision was included in first quarter 2014 results. Varian Medical Systems Beats, Earnings Flat Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:12PM CDT
Varian Medical Systems (VAR) retained its earnings per share guidance between $4.22 and $4.34 for the year, including a 16-cent charge for a patent litigation settlement.
Intuitive Surgical Lags on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:00PM CDT
Intuitive Surgical's (ISRG) earnings lagged the Zacks Consensus Estimate by a wide margin of 67 cents
IDEXX Laboratories to Release 2014 First Quarter Financial Results
PR Newswire - Tue Apr 15, 1:30PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), has scheduled the release of its 2014 first quarter financial results for Friday, April 25, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo
PR Newswire - Tue Apr 08, 1:17AM CDT
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Idexx Laboratories Larger Than S&P 500 Component LSI
TheOnlineInvestor.com - Mon Mar 31, 3:37PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Idexx Laboratories, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example LSI Corp , according to The...
Recognitions, Board Elections, Acquisitions, and Organizational Changes - Analyst Notes on Omnicare, Cooper, Mednax, IDEXX, and Hologic
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Omnicare Inc. (NYSE: OCR), The Cooper Companies Inc. (NYSE: COO), MEDNAX, Inc. (NYSE: MD), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Hologic Inc. (NASDAQ: HOLX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Idexx Laboratories Stock Rises 16.3% (IDXX)
Comtex SmarTrend(R) - Wed Mar 19, 5:15PM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 16.31% as of today's recent price of $123.74.
After Yesterday's Decline of 3.31%, Idexx Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 17, 6:10PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $123.64 to a high of $129.17. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $125.59 on volume of 627,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Idexx Laboratories (IDXX) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Mon Mar 17, 12:23PM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Idexx Laboratories Shares Up 20.2% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 12, 11:07AM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 20.18% as of today's recent price of $127.85.
IDEXX Laboratories names Daniel Junius as member of the board
M2 - Wed Mar 12, 7:59AM CDT
Diagnostics and information technology solutions for animal health care company IDEXX Laboratories (NASDAQ:IDXX) announced on Tuesday that Daniel M Junius has been elected as a member of the company's board of directors, with immediate effect.
